
|Videos|July 2, 2013
Episode 13 - Treatment Challenges for Progressive Disease
Advertisement
Episodes in this series

Because there aren’t treatment options available for the management of progressive multiple sclerosis (MS), Patricia K. Coyle, MD, explains the challenges clinicians are faced with when treating patients who transition into a progressive stage of the disease.
Dr Coyle and Leslie Fish, PharmD, explain that although the topic of when to end therapy for patients who transition into a worsening stage is controversial, it is necessary to make personalized treatment decisions.
Dr Fish further explains how the rising costs of agents for the treatment MS further complicate management of MS and affect a clinician’s decision about when to begin or end therapy for a patient.
Advertisement
Related to this article

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.

A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5

















